Author:
Feldman Steven R.,Kay Richard,Reznichenko Nataliya,Sobierska Joanna,Dias Roshan,Otto Hendrik,Haliduola Halimu N.,Sattar Abid,Ruffieux Ruth,Stroissnig Heimo,Berti Fausto
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine,Biotechnology
Reference32 articles.
1. Barbier L, Vulto AG. Interchangeability of biosimilars: overcoming the final hurdles. Drugs. 2021;81:1897–903. https://doi.org/10.1007/s40265-021-01629-4.
2. Barbier L, Ebbers HC, Declerck P, Simoens S, Vulto A, Huys I. The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review. Clin Pharmacol Ther. 2020;108:734–55. https://doi.org/10.1002/cpt.1836.
3. Kurki P, Barry S, Bourges I, Tsantili P, Wolff-Holz E. Safety, immunogenicity and interchangeability of biosimilar monoclonal antibodies and fusion proteins: a regulatory perspective. Drugs. 2021;81:1881–96. https://doi.org/10.1007/s40265-021-01601-2.
4. Considerations in demonstrating interchangeability with a reference product: guidance for industry. In: U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). 2019. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-demonstrating-interchangeability-reference-product-guidance-industry. Accessed 13 September 2022.
5. Patel PK, King CR, Feldman SR. Biologics and biosimilars. J Dermatolog Treat. 2015;26:299–302. https://doi.org/10.3109/09546634.2015.1054782.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献